The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations

被引:574
作者
Bladen, Catherine L. [1 ]
Salgado, David [2 ]
Monges, Soledad [3 ]
Foncuberta, Maria E. [3 ]
Kekou, Kyriaki [4 ]
Kosma, Konstantina [4 ,5 ]
Dawkins, Hugh [6 ]
Lamont, Leanne [6 ]
Roy, Anna J. [7 ]
Chamova, Teodora [8 ]
Guergueltcheva, Velina [8 ]
Chan, Sophelia [9 ]
Korngut, Lawrence [10 ,11 ]
Campbell, Craig [12 ]
Dai, Yi [13 ,14 ]
Wang, Jen [15 ]
Barisic, Nina [16 ]
Brabec, Petr [17 ]
Lahdetie, Jaana [18 ]
Walter, Maggie C. [19 ]
Schreiber-Katz, Olivia [19 ]
Karcagi, Veronika [20 ]
Garami, Marta [20 ]
Viswanathan, Venkatarman [21 ,22 ]
Bayat, Farhad [23 ]
Buccella, Filippo [24 ]
Kimura, En
Koeks, Zaida [25 ]
van den Bergen, Janneke C. [25 ]
Rodrigues, Miriam [26 ]
Roxburgh, Richard [26 ]
Lusakowska, Anna [27 ]
Kostera-Pruszczyk, Anna [27 ]
Zimowski, Janusz [28 ]
Santos, Rosario [29 ]
Neagu, Elena [30 ]
Artemieva, Svetlana [31 ]
Rasic, Vedrana Milic [32 ]
Vojinovic, Dina [32 ]
Posada, Manuel [33 ,34 ]
Bloetzer, Clemens [35 ]
Jeannet, Pierre-Yves [35 ]
Joncourt, Franziska [36 ]
Diaz-Manera, Jordi [37 ]
Gallardo, Eduard [37 ]
Karaduman, A. Ayse [38 ]
Topaloglu, Haluk [39 ]
El Sherif, Rasha [40 ]
Stringer, Angela [41 ]
Shatillo, Andriy V. [42 ]
机构
[1] Univ Newcastle, Inst Med Genet, John Walton Muscular Dystrophy Res Ctr, MRC Ctr Neuromuscular Dis, Newcastle Upon Tyne NE13BZ, Tyne & Wear, England
[2] Aix Marseille Univ, INSERM, GMGF UMR S 910, Marseille, France
[3] Hosp Pediat JP Garrahan, Pichincha, Argentina
[4] Univ Athens, Sch Med, Dept Med Genet, GR-11527 Athens, Greece
[5] St Sophias Childrens Hosp Thinon & Levadia Goudi, Choremio Res Lab, Athens, Greece
[6] Off Populat Hlth Genom, Dept Hlth, Perth, WA, Australia
[7] WIV ISP, Brussels, Belgium
[8] Med Univ Sofia, Dept Neurol, Sofia, Bulgaria
[9] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Pok Fu Lam, Hong Kong, Peoples R China
[10] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[11] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[12] Univ Western Ontario, Dept Paediat Clin Neurol Sci & Epidemiol, London, ON, Canada
[13] Peking Union Med Coll, Dept Neurol, Peking Union Med Coll Hosp, Beijing 100021, Peoples R China
[14] Chinese Acad Med Sci, Beijing 100730, Peoples R China
[15] China Dolls, Dept Neurol, Beijing, Peoples R China
[16] Univ Zagreb, Sch Med, Univ Hosp Ctr Zagreb KBC Zagreb, Div Paediat Neurol, Zagreb 41000, Croatia
[17] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
[18] Turku Univ, Cent Hosp, Dept Child Neurol, Turku, Finland
[19] Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany
[20] NIEH, Dept Mol Genet & Diagnost, Budapest, Hungary
[21] CHILDS Trust Med Res Fdn, Madras, Tamil Nadu, India
[22] Apollo Childrens Hosp, Madras, Tamil Nadu, India
[23] Pasteur Inst Iran, Tehran, Iran
[24] Parent Project Onlus, Rome, Italy
[25] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands
[26] Auckland DHB, Dept Neurol, Auckland, New Zealand
[27] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[28] Inst Psychiat & Neurol, Dept Genet, Warsaw, Poland
[29] Ctr Genet Med Jacinto Magalhaes, Oporto, Portugal
[30] Natl Inst Legal Med, Genet Lab, Bucharest, Romania
[31] Moscow Inst Pediat, Moscow, Russia
[32] Univ Belgrade, Fac Med, Clin Neurol & Psychiat Children & Youth, Belgrade, Serbia
[33] Inst Hlth Carlos III, Inst Rare Dis Res, Spain RDR, Madrid, Spain
[34] Inst Hlth Carlos III, CIBERER, Madrid, Spain
[35] Univ Lausanne Hosp, Neurorehabil Unit, Lausanne, Switzerland
[36] Univ Bern, Inselspital, Div Human Genet, Childrens Univ Hosp, CH-3010 Bern, Switzerland
[37] Hosp Santa CreuiSt Pau Barcelona, Serv Neurol, Unitat MalaltiesNeuromusculars, Barcelona, Spain
[38] Hacettepe Univ, Fac Hlth Sci, Dept Physiotherapy & Rehabil, Ankara, Turkey
[39] Hacettepe Childrens Hosp Med Ctr, Ankara, Turkey
[40] Ain Shams Univ, Egypt Air Hosp, Neurol & Neurogen Unit, Cairo, Egypt
[41] Epictr, Act Duchenne, London, England
[42] NAMS, Psychiat & Narcol, Inst Neurol, Kharkov, Ukraine
[43] Duchenne Connect, Hackensack, NJ USA
[44] Murdoch Univ, Ctr Comparat Gen, Murdoch, WA 6150, Australia
[45] Univ Med Ctr Freiburg, Freiburg, Germany
[46] Nationwide Childrens Hosp, Res Inst, Ctr Gene Therapy, Columbus, OH USA
[47] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands
[48] Hop Enfants La Timone, INSERM, APHM, Dept Genet Med & Biol Cellulaire, F-13385 Marseille, France
关键词
DMD; Duchenne muscular dystrophy; TREAT-NMD; rare disease registries; NONSENSE MUTATIONS; MUSCLE-CELLS; EXON; RECOMMENDATIONS; EXPRESSION; PHENOTYPE; PTC124; MODEL; ACIDS;
D O I
10.1002/humu.22758
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学];
摘要
Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).
引用
收藏
页码:395 / 402
页数:8
相关论文
共 33 条
[1]
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients [J].
Aartsma-Rus, A ;
Janson, AAM ;
Kaman, WE ;
Bremmer-Bout, M ;
den Dunnen, JT ;
Baas, F ;
van Ommen, GJB ;
van Deutekom, JCT .
HUMAN MOLECULAR GENETICS, 2003, 12 (08) :907-914
[2]
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense [J].
Aartsma-Rus, A ;
Janson, AAM ;
Kaman, WE ;
Bremmer-Bout, M ;
van Ommen, GJB ;
den Dunnen, JT ;
van Deutekom, JCT .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 74 (01) :83-92
[3]
Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule [J].
Aartsma-Rus, Annemieke ;
Van Deutekom, Judith C. T. ;
Fokkema, Ivo F. ;
Van Ommen, Gert-Jan B. ;
Den Dunnen, Johan T. .
MUSCLE & NERVE, 2006, 34 (02) :135-144
[4]
Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations [J].
Aartsma-Rus, Annemieke ;
Fokkema, Ivo ;
Verschuuren, Jan ;
Ginjaar, Leke ;
van Deutekom, Judith ;
van Ommen, Gert-Jan ;
den Dunnen, Johan T. .
HUMAN MUTATION, 2009, 30 (03) :293-299
[5]
THE STRUCTURAL AND FUNCTIONAL DIVERSITY OF DYSTROPHIN [J].
AHN, AH ;
KUNKEL, LM .
NATURE GENETICS, 1993, 3 (04) :283-291
[6]
ARE CPG SITES MUTATION HOT-SPOTS IN THE DYSTROPHIN GENE [J].
AKALIN, N ;
ZIETKIEWICZ, E ;
MAKALOWSKI, W ;
LABUDA, D .
HUMAN MOLECULAR GENETICS, 1994, 3 (08) :1425-1426
[7]
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle [J].
Arechavala-Gomeza, V. ;
Graham, I. R. ;
Popplewell, L. J. ;
Adams, A. M. ;
Aartsma-Rus, A. ;
Kinali, M. ;
Morgan, J. E. ;
Van Deutekom, J. C. ;
Wilton, S. D. ;
Dickson, G. ;
Muntoni, F. .
HUMAN GENE THERAPY, 2007, 18 (09) :798-810
[8]
UMD (Universal Mutation Database):: 2005 update [J].
Béroud, C ;
Hamroun, D ;
Collod-Béroud, G ;
Boileau, C ;
Soussi, T ;
Claustres, M .
HUMAN MUTATION, 2005, 26 (03) :184-191
[9]
Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63 % of patients with Duchenne muscular dystrophy [J].
Beroud, Christophe ;
Tuffery-Giraud, Sylvie ;
Matsuo, Masafumi ;
Hamroun, Dalil ;
Humbertclaude, Wronique ;
Monnier, Nicole ;
Moizard, Marie-Pierre ;
Voelckel, Marie-Antoinette ;
Calemard, Laurence Michel ;
Boisseau, Pierre ;
Blayau, Martine ;
Philippe, Christophe ;
Cossee, Mireille ;
Pages, Michel ;
Rivier, Franois ;
Danos, Olivier ;
Garcia, Luis ;
Claustres, Mireille .
HUMAN MUTATION, 2007, 28 (02) :196-202
[10]
The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia [J].
Bladen, Catherine L. ;
Rafferty, Karen ;
Straub, Volker ;
Monges, Soledad ;
Moresco, Angelica ;
Dawkins, Hugh ;
Roy, Anna ;
Chamova, Teodora ;
Guergueltcheva, Velina ;
Korngut, Lawrence ;
Campbell, Craig ;
Dai, Yi ;
Barisic, Nina ;
Kos, Tea ;
Brabec, Petr ;
Rahbek, Jes ;
Lahdetie, Jaana ;
Tuffery-Giraud, Sylvie ;
Claustres, Mireille ;
Leturcq, France ;
Ben Yaou, Rabah ;
Walter, Maggie C. ;
Schreiber, Olivia ;
Karcagi, Veronika ;
Herczegfalvi, Agnes ;
Viswanathan, Venkatarman ;
Bayat, Farhad ;
Sarmiento, Isis de la Caridad Guerrero ;
Ambrosini, Anna ;
Ceradini, Francesca ;
Kimura, En ;
van den Bergen, Janneke C. ;
Rodrigues, Miriam ;
Roxburgh, Richard ;
Lusakowska, Anna ;
Oliveira, Jorge ;
Santos, Rosario ;
Neagu, Elena ;
Butoianu, Niculina ;
Artemieva, Svetlana ;
Rasic, Vedrana Milic ;
Posada, Manuel ;
Palau, Francesc ;
Lindvall, Bjorn ;
Bloetzer, Clemens ;
Karaduman, Ayse ;
Topaloglu, Haluk ;
Inal, Serap ;
Oflazer, Piraye ;
Stringer, Angela .
HUMAN MUTATION, 2013, 34 (11) :1449-1457